| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Vasishta S Tatapudi | Q58048160 |
| P2093 | author name string | Robert A Montgomery | |
| P2860 | cites work | Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome | Q24622189 |
| Eculizumab for dense deposit disease and C3 glomerulonephritis | Q24632330 | ||
| Delayed graft function in the kidney transplant | Q26824506 | ||
| Complement. First of two parts | Q28210663 | ||
| Membranoproliferative glomerulonephritis--a new look at an old entity | Q28262402 | ||
| Eculizumab and renal transplantation in a patient with CAPS | Q28281405 | ||
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor | Q28565242 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Combined kidney and liver transplantation for familial haemolytic uraemic syndrome | Q33342484 | ||
| Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background | Q33376237 | ||
| Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome | Q33395251 | ||
| Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report | Q33395870 | ||
| Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein | Q33400705 | ||
| Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies | Q33403607 | ||
| Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome | Q33408211 | ||
| Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts | Q33415390 | ||
| Atypical hemolytic uremic syndrome recurrence after kidney transplantation | Q33415949 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | Q34567835 | ||
| Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies | Q83203130 | ||
| Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody | Q83387327 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant | Q85570146 | ||
| C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study | Q86955576 | ||
| Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study | Q89210051 | ||
| The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 | ||
| Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. | Q36827985 | ||
| Thrombophilia and arteriovenous fistula survival in ESRD | Q36910895 | ||
| Review article: Luminex technology for HLA antibody detection in organ transplantation | Q37389868 | ||
| Therapeutic potential of complement modulation | Q37644190 | ||
| Rejection of the kidney allograft | Q37798268 | ||
| The role of complement in antibody-mediated rejection in kidney transplantation | Q38048605 | ||
| Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. | Q38048606 | ||
| Complement as a multifaceted modulator of kidney transplant injury | Q38217273 | ||
| Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema | Q39280433 | ||
| Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients | Q39730025 | ||
| Predominant role for C5b-9 in renal ischemia/reperfusion injury. | Q40437461 | ||
| Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function | Q40682324 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| Summary of FDA antibody-mediated rejection workshop | Q42598786 | ||
| Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation | Q43840841 | ||
| Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". | Q44550364 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| Identifying specific causes of kidney allograft loss. | Q45810388 | ||
| A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. | Q45932199 | ||
| Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. | Q45964495 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. | Q47206753 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports | Q47845812 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. | Q50654391 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. | Q51333222 | ||
| C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. | Q53225887 | ||
| Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. | Q53591741 | ||
| Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. | Q55052886 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA–Incompatible Kidney Transplantation | Q58048136 | ||
| Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation | Q58048140 | ||
| Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection | Q67773387 | ||
| The quality of life of patients with end-stage renal disease | Q69938030 | ||
| Improved graft survival after renal transplantation in the United States, 1988 to 1996 | Q73502580 | ||
| Call for revolution: a new approach to describing allograft deterioration | Q74407750 | ||
| Risk of renal allograft loss from recurrent glomerulonephritis | Q74445034 | ||
| Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch | Q77309279 | ||
| Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') | Q79921621 | ||
| Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies | Q81414156 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 91-100 | |
| P577 | publication date | 2017-04-20 | |
| P1433 | published in | Current transplantation reports | Q27725344 |
| P1476 | title | Pharmacologic Complement Inhibition in Clinical Transplantation | |
| P478 | volume | 4 |
| Q92222061 | A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates |
| Q92035579 | Clinical promise of next-generation complement therapeutics |
| Q91713139 | Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/βcatenin signaling after ischemia/reperfusion injury |
| Q95840971 | Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage |
Search more.